You are here: Industry Insights > Hookipa

News List

Gilead, Hookipa pen hepatitis B, HIV research collaboration fiercebiotech
June 11, 2018
Gilead has licensed immunization technologies from Hookipa Biotech for use against hepatitis B and HIV. The big biotech is paying $10 million (€8.5 million) upfront and committing to milestones that could exceed $400 million to snag exclusive rights to tw
Gilead backs $60M Hookipa round to fund immunotherapy R&D fiercebiotech
December 12, 2017
Gilead has joined Boehringer Ingelheim and Takeda on the list of investors in Hookipa Biotech.
Hookipa Biotech announces data showing TheraT turns cold tumours hot cphi-online
June 01, 2017
TheraT mediated alarmin release crucial for active immunization in cancer immunotherapy.
Dr Igor Matushansky Appointed Global Head, Research and Development of Hookipa Biotech b3cnewswire
March 07, 2017
Hookipa Biotech AG, a company pioneering a new class of immunotherapies for oncology and infectious diseases, today announces the appointment of Igor Matushansky, M.D., Ph.D. as Global Head, Research and Development. The appointment is effective from toda